Overview

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

Phase:

Phase 1

Details

Lead Sponsor:

Mateon Therapeutics

Treatments:

Combretastatin